GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prestige Biologics Co Ltd (XKRX:334970) » Definitions » Revenue

Prestige Biologics Co (XKRX:334970) Revenue : ₩2,304 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Prestige Biologics Co Revenue?

Prestige Biologics Co's revenue for the three months ended in Mar. 2024 was ₩639 Mil. Its revenue for the trailing twelve months (TTM) ended in Mar. 2024 was ₩2,304 Mil. Prestige Biologics Co's Revenue per Share for the three months ended in Mar. 2024 was ₩10.45. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was ₩37.69.

Warning Sign:

Prestige Biologics Co Ltd revenue per share has been in decline over the past 3 years.

During the past 12 months, the average Revenue per Share Growth Rate of Prestige Biologics Co was 12882.60% per year. During the past 3 years, the average Revenue per Share Growth Rate was -62.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 7 years, Prestige Biologics Co's highest 3-Year average Revenue per Share Growth Rate was -62.70% per year. The lowest was -62.70% per year. And the median was -62.70% per year.


Prestige Biologics Co Revenue Historical Data

The historical data trend for Prestige Biologics Co's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prestige Biologics Co Revenue Chart

Prestige Biologics Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Revenue
Get a 7-Day Free Trial - 184.75 - 3,226.84 15.57

Prestige Biologics Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.52 53.56 914.50 750.77 638.83

Competitive Comparison of Prestige Biologics Co's Revenue

For the Biotechnology subindustry, Prestige Biologics Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prestige Biologics Co's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prestige Biologics Co's Revenue distribution charts can be found below:

* The bar in red indicates where Prestige Biologics Co's Revenue falls into.



Prestige Biologics Co Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩2,304 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Prestige Biologics Co  (XKRX:334970) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Prestige Biologics Co Revenue Related Terms

Thank you for viewing the detailed overview of Prestige Biologics Co's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Prestige Biologics Co (XKRX:334970) Business Description

Traded in Other Exchanges
N/A
Address
197, Osongsaengmyeong 1-ro, Osong-eup, Heungdeok-gu, Chungcheongbuk-do, Cheongju-si, KOR, 28161
Prestige Biologics Co Ltd is a CDMO-dedicated company that provides solutions of development and manufacturing tasks throughout the stages from the research/development, engineering, clinical production, commercial production, clinical support, and IND & BLA filing of biopharmaceutical products. Its product candidate includes HD201 (Herceptin Biosimilar).

Prestige Biologics Co (XKRX:334970) Headlines

No Headlines